MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
NovaBay Pharmaceuticals ROE Ratio 2011-2026 | NBY
Annual ROE Ratio NovaBay Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5599.22 | -290.89 | -100.51 | -57.26 | -89.62 | -992.6 | -132.12 | -285.39 | -185.2 | 372.17 | -822.19 | -188.37 | -50.02 | -54.42 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5599.22 | -992.6 | 194.49 |
Quarterly ROE Ratio NovaBay Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -150.56 | -147.02 | 155.14 | -1864.92 | -1889.89 | -1801.8 | -2082.46 | -68.31 | -69.29 | -45.31 | -35.22 | -15.3 | -39.74 | -63.2 | -66.1 | -54.85 | -81.0 | -82.7 | -102.5 | -75.38 | -104.36 | -107.19 | -327.85 | -716.55 | -747.59 | -749.66 | -524.69 | -106.52 | -240.09 | -342.61 | -377.54 | -355.2 | -407.81 | -326.85 | -297.73 | -161.99 | -59.17 | 96.27 | 230.01 | -17.23 | -245.53 | -576.65 | -831.72 | -580.41 | -625.6 | -442.48 | -330.82 | -796.31 | -795.74 | -749.99 | -718.3 | -33.29 | -32.16 | -31.59 | -11.2 | -15.59 | 1.13 | 4.55 | -21.28 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 230.01 | -2082.46 | -356.91 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.44 | -4.32 % | $ 1.03 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K |  USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
ADMA Biologics
ADMA
|
30.78 | $ 15.36 | -2.17 % | $ 3.66 B | USA |
 |
Cellectis S.A.
CLLS
|
-26.25 | $ 3.53 | -3.54 % | $ 116 M | France |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
6.05 | $ 20.28 | 0.65 % | $ 2.56 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
2477.67 | - | -19.68 % | $ 18.4 M | Canada |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.79 | -1.15 % | $ 4.31 M | China |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.51 | 1.35 % | $ 385 M | Britain |
 |
China SXT Pharmaceuticals
SXTC
|
-21.4 | $ 2.01 | -1.36 % | $ 2.86 M | China |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-46.04 | $ 0.67 | 7.08 % | $ 624 K |  Israel |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 14.05 | -1.44 % | $ 206 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
-4.59 | $ 74.36 | -1.64 % | $ 1.44 B | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-116.29 | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-207.46 | $ 162.43 | 0.6 % | $ 8.08 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
18.68 | $ 8.49 | -0.18 % | $ 1.75 B | USA |
 |
BridgeBio Pharma
BBIO
|
35.13 | $ 65.66 | -0.78 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
149.7 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-1239.35 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
BioLineRx Ltd.
BLRX
|
-136.27 | $ 2.69 | -0.74 % | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
5.73 | $ 61.3 | 1.21 % | $ 11.8 B | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 7.79 | -5.75 % | $ 1.28 B | Britain |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |